SCHEMBL22032449

SCHEMBL22032449

CCCCCCCCCC(CC)CC(C)C=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.44
ADH1C P00326 1/20 0.44
ADH1A P07327 1/20 0.44
ADH4 P08319 1/20 0.44
ADH7 P40394 1/20 0.44
LMNA P02545 1/20 0.42
TSHR P16473 3/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP3A4 P08684 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.38
PRSS1 P07477 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36
OPRM1 P35372 1/20 0.35
ACE2 Q9BYF1 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TRPA1 O75762 1/20 0.35
DDAH1 O94760 1/20 0.35
GAPDH P04406 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21142990 0.92 ALDH1A1 (0.48) ADH1BADH1CADH1AADH4ADH7
SCHEMBL6859062 0.84 TSHR (0.37) TSHRALDH1A1CYP3A4SMN1; SMN2
SCHEMBL18092233 0.82 LMNA (0.34) LMNATSHRALDH1A1CYP3A4SMN1; SMN2
SCHEMBL10534445 0.81 TSHR (0.55) ADH1BADH1CADH1AADH4ADH7
SCHEMBL8704925 0.80 ADH1B (0.47) ADH1BADH1CADH1AADH4ADH7
SCHEMBL8670139 0.79 TSHR (0.59) ADH1BADH1CADH1AADH4ADH7
SCHEMBL22700 0.79 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL3844523 0.79 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL16350215 0.79 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7
SCHEMBL1869609 0.79 ADH1B (0.54) ADH1BADH1CADH1AADH4ADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807646-B2 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2023-11-07 US disclosed
EP-3746432-B1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LTD (GB) 2022-12-14 EP disclosed
US-20220033397-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LTD (GB) 2022-02-03 US disclosed
EP-3890829-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) Almac Discovery Limited (GB) 2021-10-13 EP disclosed
US-20210070773-A1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2021-03-11 US disclosed
WO-2020115501-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2020-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220033397-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) USP19, USP16, USP18 ADH1B 2392/4885ADH1C 3404/4885ADH1A 3847/4885
US-11807646-B2 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) USP19, USP16, USP18 ADH1B 1936/4885ADH1C 788/4885ADH1A 2353/4885
US-20210070773-A1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) USP19, USP16, USP18 ADH1B 1936/4885ADH1C 788/4885ADH1A 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.